Valuation dashboard for Jupiter Neurosciences, Inc. (JUNS) with P/E N/A, P/B -4.27, EV/EBITDA -0.19 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Jupiter Neurosciences, Inc. is a pharmaceutical company engaged in clinical-stage research and development. Its primary focus is on advancing a resveratrol-based platform product, with the main objective of addressing neuro-inflammation. The company's pipeline includes several drug candidates: JNS101 is undergoing Phase II trials for Friedreich's Ataxia, a rare neurological disorder that damages the nervous system and causes mobility issues.
Analysis Summary
Jupiter Neurosciences, Inc. reported revenue of $21796 in the most recent fiscal year, growing at a 5-year CAGR of -54.6%.
Trailing-twelve-month margins: gross margin 88.3%, operating margin -151.7%, net margin -142.2%.
At the current price of $2.93, JUNS has negative trailing earnings (P/E not meaningful) and an ROE of 7.47%. Market capitalisation stands at $1M.
Balance sheet quality for JUNS: current ratio of 0.7. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | -4.27 |
| EV / EBITDA | -0.19 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| JUNS | Jupiter Neurosciences, Inc. | $1M | 7.5% | ||
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $2.93 |
| Market Cap | $1M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | 747.33% |
| Return on Invested Capital | -709.40% |
| Return on Assets | -247.39% |
| Gross Margin | 88.34% |
| Operating Margin | -15166.68% |
| Net Margin | -14220.12% |
Related companies: ABVC · ALGS · FGEN · GNTA · GRCE · KZR · MRSN
Explore sector: Healthcare · Biotechnology
More sections of JUNS: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks